跳转至内容
Merck
CN
  • Solid phase microextraction, mass spectrometry and metabolomic approaches for detection of potential urinary cancer biomarkers--a powerful strategy for breast cancer diagnosis.

Solid phase microextraction, mass spectrometry and metabolomic approaches for detection of potential urinary cancer biomarkers--a powerful strategy for breast cancer diagnosis.

Talanta (2012-01-31)
Catarina L Silva, Mário Passos, José S Câmara
摘要

A sensitive assay to identify volatile organic metabolites (VOMs) as biomarkers that can accurately diagnose the onset of breast cancer using non-invasively collected clinical specimens is ideal for early detection. Therefore the aim of this study was to establish the urinary metabolomic profile of breast cancer patients and healthy individuals (control group) and to explore the VOMs as potential biomarkers in breast cancer diagnosis at early stage. Solid-phase microextraction (SPME) using CAR/PDMS sorbent combined with gas chromatography-mass spectrometry was applied to obtain metabolomic information patterns of 26 breast cancer patients and 21 healthy individuals (controls). A total of seventy-nine VOMs, belonging to distinct chemical classes, were detected and identified in control and breast cancer groups. Ketones and sulfur compounds were the chemical classes with highest contribution for both groups. Results showed that excretion values of 6 VOMs among the total of 79 detected were found to be statistically different (p<0.05). A significant increase in the peak area of (-)-4-carene, 3-heptanone, 1,2,4-trimethylbenzene, 2-methoxythiophene and phenol, in VOMs of cancer patients relatively to controls was observed. Statistically significant lower abundances of dimethyl disulfide were found in cancer patients. Bioanalytical data were submitted to multivariate statistics [principal component analysis (PCA)], in order to visualize clusters of cases and to detect the VOMs that are able to differentiate cancer patients from healthy individuals. Very good discrimination within breast cancer and control groups was achieved. Nevertheless, a deep study using a larger number of patients must be carried out to confirm the results.

材料
Product Number
品牌
产品描述

Sigma-Aldrich
丙酮, ACS reagent, ≥99.5%
Sigma-Aldrich
乙酸, glacial, ACS reagent, ≥99.7%
Sigma-Aldrich
丙酮, suitable for HPLC, ≥99.9%
Sigma-Aldrich
乙酸, glacial, ReagentPlus®, ≥99%
Sigma-Aldrich
丙酮, HPLC Plus, for HPLC, GC, and residue analysis, ≥99.9%
Sigma-Aldrich
丙酮, Laboratory Reagent, ≥99.5%
Sigma-Aldrich
2-丁酮, ACS reagent, ≥99.0%
Sigma-Aldrich
乙酸, glacial, ≥99.99% trace metals basis
Sigma-Aldrich
乙酸, glacial, puriss. p.a., ACS reagent, reag. ISO, reag. Ph. Eur., ≥99.8%
Sigma-Aldrich
乙酸, glacial, puriss., meets analytical specification of Ph. Eur., BP, USP, FCC, 99.8-100.5%
Sigma-Aldrich
乙酸 溶液, suitable for HPLC
Sigma-Aldrich
4-甲基-2-戊酮, suitable for HPLC, ≥99.5%
Sigma-Aldrich
1-辛醇, ACS reagent, ≥99%
Sigma-Aldrich
丙酮, suitable for HPLC, ≥99.8%
Sigma-Aldrich
丙酮, puriss. p.a., ACS reagent, reag. ISO, reag. Ph. Eur., ≥99.5% (GC)
Sigma-Aldrich
4-甲基-2-戊酮, ACS reagent, ≥98.5%
Sigma-Aldrich
苯酚 溶液, BioReagent, Equilibrated with 10 mM Tris HCl, pH 8.0, 1 mM EDTA, Molecular Biology
Sigma-Aldrich
苯甲酸, ACS reagent, ≥99.5%
Sigma-Aldrich
辛酸, ≥99%
Sigma-Aldrich
苯酚, puriss., meets analytical specification of Ph. Eur., BP, USP, ≥99.5% (GC), crystalline (detached)
Sigma-Aldrich
丙酮, ACS reagent, ≥99.5%
Sigma-Aldrich
1-辛醇, suitable for HPLC, ≥99%
Supelco
苯甲酸, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
丙酮, analytical standard
Sigma-Aldrich
愈创木酚, oxidation indicator
Sigma-Aldrich
苯酚 溶液, Saturated with 0.01 M citrate buffer, pH 4.3 ± 0.2, BioReagent, Molecular Biology
Sigma-Aldrich
己酸, ≥99%
Sigma-Aldrich
1-辛醇, ReagentPlus®, 99%
Sigma-Aldrich
苯酚, ≥99%
Sigma-Aldrich
正己醛, 98%